148 related articles for article (PubMed ID: 28431161)
21. Enhanced binding activity observed between anti-carcinoembryonic monoclonal antibodies.
Wellerson R; Kaplan P
Hybridoma; 1986; 5(3):199-213. PubMed ID: 2429910
[TBL] [Abstract][Full Text] [Related]
22. Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues.
Studnicka GM; Soares S; Better M; Williams RE; Nadell R; Horwitz AH
Protein Eng; 1994 Jun; 7(6):805-14. PubMed ID: 7937712
[TBL] [Abstract][Full Text] [Related]
23. Construction and expression of two mouse-human chimeric antibodies with high specificity and affinity for carcinoembryonic antigen.
Arakawa F; Haruno M; Kuroki M; Kanda H; Watanabe T; Misumi Y; Matsuoka Y
Hybridoma; 1993 Aug; 12(4):365-79. PubMed ID: 8244416
[TBL] [Abstract][Full Text] [Related]
24. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
[TBL] [Abstract][Full Text] [Related]
25. A monoclonal antibody generated against a recombinant peptide fragment of the B3 domain of carcinoembryonic antigen reacts with intact carcinoembryonic antigen.
Hagendorff G; Hanes J; von der Kammer H; Scheit KH
Biochim Biophys Acta; 1995 Feb; 1260(3):259-68. PubMed ID: 7873599
[TBL] [Abstract][Full Text] [Related]
26. Self recognition in the Ig superfamily. Identification of precise subdomains in carcinoembryonic antigen required for intercellular adhesion.
Taheri M; Saragovi U; Fuks A; Makkerh J; Mort J; Stanners CP
J Biol Chem; 2000 Sep; 275(35):26935-43. PubMed ID: 10864933
[TBL] [Abstract][Full Text] [Related]
27. De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide.
Entzminger KC; Hyun JM; Pantazes RJ; Patterson-Orazem AC; Qerqez AN; Frye ZP; Hughes RA; Ellington AD; Lieberman RL; Maranas CD; Maynard JA
Sci Rep; 2017 Aug; 7(1):10295. PubMed ID: 28860479
[TBL] [Abstract][Full Text] [Related]
28. Template-Catalyzed, Disulfide Conjugation of Monoclonal Antibodies Using a Natural Amino Acid Tag.
King JD; Ma Y; Kuo YC; Bzymek KP; Goodstein LH; Meyer K; Moore RE; Crow D; Colcher DM; Singh G; Horne DA; Williams JC
Bioconjug Chem; 2018 Jun; 29(6):2074-2081. PubMed ID: 29763554
[TBL] [Abstract][Full Text] [Related]
29. Contribution of a single heavy chain residue to specificity of an anti-digoxin monoclonal antibody.
Schildbach JF; Shaw SY; Bruccoleri RE; Haber E; Herzenberg LA; Jager GC; Jeffrey PD; Panka DJ; Parks DR; Near RI
Protein Sci; 1994 May; 3(5):737-49. PubMed ID: 8061604
[TBL] [Abstract][Full Text] [Related]
30. First-In-Human Pilot PET Immunoimaging Study of
Wong JYC; Yamauchi DM; Adhikarla V; Simpson J; Frankel PH; Fong Y; Melstrom KA; Chen YJ; Salehian BD; Woo Y; Dandapani SV; Colcher DM; Poku EK; Yazaki PJ; Wu AM; Shively JE
Cancer Biother Radiopharm; 2023 Feb; 38(1):26-37. PubMed ID: 36154291
[No Abstract] [Full Text] [Related]
31. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.
Iwahashi M; Milenic DE; Padlan EA; Bei R; Schlom J; Kashmiri SV
Mol Immunol; 1999; 36(15-16):1079-91. PubMed ID: 10698310
[TBL] [Abstract][Full Text] [Related]
32. Mechanically interlocked functionalization of monoclonal antibodies.
Bzymek KP; Puckett JW; Zer C; Xie J; Ma Y; King JD; Goodstein LH; Avery KN; Colcher D; Singh G; Horne DA; Williams JC
Nat Commun; 2018 Apr; 9(1):1580. PubMed ID: 29679060
[TBL] [Abstract][Full Text] [Related]
33.
Mohajershojai T; Jha P; Boström A; Frejd FY; Yazaki PJ; Nestor M
Front Oncol; 2022; 12():849338. PubMed ID: 35433442
[TBL] [Abstract][Full Text] [Related]
34. Affinity Maturation of a Cyclic Peptide Handle for Therapeutic Antibodies Using Deep Mutational Scanning.
van Rosmalen M; Janssen BM; Hendrikse NM; van der Linden AJ; Pieters PA; Wanders D; de Greef TF; Merkx M
J Biol Chem; 2017 Jan; 292(4):1477-1489. PubMed ID: 27974464
[TBL] [Abstract][Full Text] [Related]
35. Protein epitopes in carcinoembryonic antigen. Report of the ISOBM TD8 workshop.
Bjerner J; Lebedin Y; Bellanger L; Kuroki M; Shively JE; Varaas T; Nustad K; Hammarström S; Børmer OP
Tumour Biol; 2002; 23(4):249-62. PubMed ID: 12499780
[TBL] [Abstract][Full Text] [Related]
36. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant.
Mimoto F; Igawa T; Kuramochi T; Katada H; Kadono S; Kamikawa T; Shida-Kawazoe M; Hattori K
MAbs; 2013; 5(2):229-36. PubMed ID: 23406628
[TBL] [Abstract][Full Text] [Related]
37. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.
Karacay H; Sharkey RM; McBride WJ; Griffiths GL; Qu Z; Chang K; Hansen HJ; Goldenberg DM
Bioconjug Chem; 2002; 13(5):1054-70. PubMed ID: 12236788
[TBL] [Abstract][Full Text] [Related]
38. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation.
Kettleborough CA; Saldanha J; Heath VJ; Morrison CJ; Bendig MM
Protein Eng; 1991 Oct; 4(7):773-83. PubMed ID: 1798701
[TBL] [Abstract][Full Text] [Related]
39. Processing of carcinoembryonic antigen by Kupffer cells: recognition of a penta-peptide sequence.
Gangopadhyay A; Thomas P
Arch Biochem Biophys; 1996 Oct; 334(1):151-7. PubMed ID: 8837750
[TBL] [Abstract][Full Text] [Related]
40. Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody.
Gerstner RB; Carter P; Lowman HB
J Mol Biol; 2002 Aug; 321(5):851-62. PubMed ID: 12206766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
